###begin article-title 0
Association of polymorphism in genes encoding kappaB inhibitors (IkappaB) with susceptibility to and phenotype of Graves' disease: a case-control study
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 320 325 308 313 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IKBL </italic>
###xml 365 372 349 356 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NFKBIA </italic>
Genes related to the nuclear factor-kappaB (NF-kappaB), a key transcription factor involved in regulation of immune responses, are interesting candidates for association studies in autoimmune disorders. The aim of this study was to investigate an association of polymorphisms in two genes encoding NF-kappaB inhibitors: IKBL (encoding inhibitor of kappaB-like) and NFKBIA (encoding kappaB inhibitor alpha), withsusceptibility to and phenotype of Graves' disease (GD).
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 179 184 179 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IKBL </italic>
###xml 327 334 327 334 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NFKBIA </italic>
###xml 66 74 <span type="species:ncbi:9606">patients</span>
A population-based, case-control association study comprising 481 patients with GD and 455 healthy controls was performed. We analyzed 3 single nucleotide polymorphisms (SNPs) in IKBL [promoter region -62T/A substitution (rs2071592), intron 1 C/T substitution (rs2071591) and exon 4 T/C substitution (rs3130062)] and 3 SNPs in NFKBIA [G/A substitution in 3' untranslated region (rs696) and two promoter region polymorphisms -297C/T (rs2233409) and -826C/T (rs2233406)] by the PCR-restriction fragment length polymorphism (RFLP) method.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 16 21 16 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IKBL </italic>
###xml 169 171 169 171 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-4</sup>
###xml 286 291 286 291 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IKBL </italic>
###xml 305 313 305 313 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1</italic>
###xml 331 333 331 333 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-4</sup>
###xml 353 360 353 360 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NFKBIA </italic>
###xml 592 594 592 594 <sub xmlns:xlink="http://www.w3.org/1999/xlink">c </sub>
###xml 647 649 647 649 <sub xmlns:xlink="http://www.w3.org/1999/xlink">c </sub>
The two SNPs in IKBL (rs2071592 and rs2071591) were in a strong linkage disequilibrium (D' = 0.835) and the AT haplotype was associated with susceptibility to GD (p < 10-4, OR = 1.61 [95%CI:1.21-2.14]). Moreover subgroup analysis revealed a gen-gen interaction between the investigated IKBL haplotype and HLA-DRB1*03 allele (p < 10-4). The investigated NFKBIA SNPs were not associated with susceptibility to GD. However, when correlated with phenotype, the -297T (rs2233409) and -826T (rs2233406) alleles were associated with the development of clinically evident ophthalmophaty (p = 0.004, pc = 0.07, OR = 1.65 [95%CI: 1.18-2.38] and p = 0.002, pc = 0.036, OR = 1.67 [95%CI: 1.20-2.36], respectively).
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
Our results suggest that SNPs in genes encoding NF-kappaB inhibitors may contribute to the development and clinical phenotype of GD.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 306 307 298 299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
The nuclear factor-kappaB (NF-kappaB) is an ubiquitous transcription factor of particular importance in normal inflammatory and immune responses and there is a growing amount of evidence that its deregulated activation may play a key role during development of common inflammatory and autoimmune diseases [1].
###end p 11
###begin p 12
###xml 567 571 559 563 <italic xmlns:xlink="http://www.w3.org/1999/xlink">via </italic>
###xml 1480 1481 1395 1396 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
In mammals the NF-kappaB family consists of two types of proteins: the first group includes p105 and p100 that after proteolysis generate short active molecules (p50 and p52, respectively); whereas the second group includes p65, c-Rel and RelB proteins, that posses transcriptional activations domains. Both groups are characterized by the presence of a Rel homology domain which contains a nuclear localization sequence (NLS) and is involved in DNA binding. In non-stimulated cells the NF-kappaB proteins form homo- or heterodimers that are sequestered in cytoplasm via interaction with kappaB inhibitors (IkappaB). The IkappaB family comprises several members, including IkappaBalpha, IkappaBbeta, IkappaBepsilon and other related proteins (such as inhibitor of kappaB-like - IkappaBL or Bcl-3) that interact with NLS in the NF-kappaB proteins and in this way prevent their nuclear translocation. Numerous activating signals can trigger transduction pathways leading to dissociation of NF-kappaB from IkappaBs. The first step of this process involves activation of IkappaB kinases (IKK). IKK phosphorylate serine residuals in the N-terminal part of the IkappaB proteins that creates a binding site for subunits of the ubiquitin ligase complex and results in rapid polyubiquitination of IkappaB followed by its proteasomal degradation. Dissociation of IkappaB exposes the NLS in NF-kappaB proteins leading to their nuclear translocation and binding to promoters of target genes [2].
###end p 12
###begin p 13
###xml 194 195 182 183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 575 576 555 556 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 861 862 837 838 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 863 865 839 841 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
Therefore the coordinated degradation and resynthesis of the IkappaB proteins regulates NF-kappaB activity and any change in this delicate balance can interfere with normal NF-kappaB functions [3]. Given the important role of the NF-kappaB transduction pathway in immune responses, NF-kappaB related genes are interesting candidates for susceptibility genes in autoimmune disorders. In our previous study we found that a promoter polymorphism (-94ins/del ATTG) in the gene encoding p105/p50, may be associated with susceptibility to and/or phenotype of Graves' disease (GD) [4]. Polymorphism within genes encoding IkappaB proteins were found to be associated with development of other autoimmune conditions including: multiple sclerosis, rheumatoid arthritis, type 1 diabetes mellitus, systemic lupus erythematosus and Crohn's disease in different populations [5-12].
###end p 13
###begin p 14
###xml 147 152 143 148 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IKBL </italic>
###xml 174 181 166 173 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NFKBIA </italic>
###xml 264 269 248 253 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IKBL </italic>
###xml 273 280 257 264 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NFKBIA </italic>
###xml 702 710 682 690 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1</italic>
###xml 715 722 695 702 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA-4 </italic>
###xml 732 739 712 719 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTPN22 </italic>
In the present study first, we analyzed an association of selected, potentially functional, polymorphisms in two genes encoding kappaB inhibitors: IKBL encoding IkappaBL and NFKBIA encoding IkappaBalpha with susceptibility to GD in Polish Caucasians. The analyzed IKBL and NFKBIA single nucleotide polymorphisms (SNPs) were selected based on previous associations studies in other autoimmune diseases. Next, we searched for a correlation with clinical phenotype of GD (gender, age of disease onset, presence of ophthalmophaty and family history of autoimmune thyroid diseases - AITD). Finally, we analyzed gene-gene interactions between IkappaB alleles and other established GD susceptibility markers (HLA-DRB1*03, CTLA-4 49A/G and PTPN22 1858C/T).
###end p 14
###begin title 15
Subjects and methods
###end title 15
###begin title 16
Subjects
###end title 16
###begin p 17
###xml 149 151 149 151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 249 250 249 250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
###xml 606 614 <span type="species:ncbi:9606">Patients</span>
Patients with GD (N = 481) were consecutively recruited from the Department of Endocrinology, Medical University of Warsaw, as described previously [13]. All individuals were of Caucasian origin and their clinical characteristics are shown in Table 1. The diagnosis of GD was based on clinical and biochemical symptoms of hyperthyroidism and was confirmed by the presence of diffuse goiter, detectable TSH receptor autoantibodies (TRAK Lumitest, B.R.A.H.M.S Diagnostica GmbH, Germany) and/or increased radioiodine uptake. The severity of ophtalmopathy was assessed according to the NOSPECS classification. Patients with proptosis (NOSPECS class III), extraocular muscle dysfunction (class IV), exposure keratitis (class V) and optic neuropathy (class VI) were considered clinically evident.
###end p 17
###begin p 18
###xml 28 36 <span type="species:ncbi:9606">patients</span>
Clinical characteristics of patients with Graves' disease (GD).
###end p 18
###begin p 19
###xml 14 22 <span type="species:ncbi:9606">patients</span>
N - number of patients available for analysis.
###end p 19
###begin p 20
* Age of onset and disease duration are presented as mean +/- SD.
###end p 20
###begin p 21
AITD - autoimmune thyroid diseases.
###end p 21
###begin p 22
###xml 301 313 <span type="species:ncbi:9606">participants</span>
The control group comprised 455 ethnically matched healthy subjects (119 male, 336 female, mean age 30.47 ( +/- 10.07 years)) who had no family history of autoimmune diseases. The research program was approved by the Local Ethical Committees, and written informed consent was obtained from all of the participants.
###end p 22
###begin title 23
Genotyping
###end title 23
###begin p 24
###xml 93 95 93 95 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 146 151 146 151 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IKBL </italic>
###xml 155 162 155 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NFKBIA </italic>
###xml 337 338 337 338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
###xml 420 425 420 425 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IKBL </italic>
###xml 633 640 633 640 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NFKBIA </italic>
Genomic DNA was extracted from peripheral blood mononuclear cells by the salting-out method [14]. Genotyping of the selected polymorphisms in the IKBL and NFKBIA genes was performed by PCR amplification followed by digestion with a proper restriction enzyme (restriction fragment length polymorphism method - RFLP) [see Additional files 1]. The obtained restriction fragments were visualized on a 3% agarose gel. In the IKBL gene three polymorphisms were analyzed: a T/A substitution in position -62 of the promoter (rs2071592), a C/T substitution in intron 1 (rs2071591) and a T/C substitution in exon 4 (rs3130062), whereas in the NFKBIA gene: a G/A substitution in 3' untranslated region (3'UTR, rs696) and two promoter polymorphisms: a C/T substitution in position -297 (rs2233409) and C/T substitution in position -826 (rs2233406) were studied.
###end p 24
###begin p 25
###xml 18 26 18 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1</italic>
###xml 28 35 28 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA-4 </italic>
###xml 39 46 39 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTPN22 </italic>
###xml 98 100 98 100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 101 103 101 103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 104 106 104 106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
Genotyping of the HLA-DRB1, CTLA-4 and PTPN22 polymorphisms was performed as reported previously [13,15,16].
###end p 25
###begin title 26
Statistical analysis
###end title 26
###begin p 27
###xml 68 69 66 67 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 326 327 324 325 <sub xmlns:xlink="http://www.w3.org/1999/xlink">c</sub>
###xml 435 437 433 435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 618 620 616 618 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 723 730 721 728 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al. </italic>
###xml 731 733 729 731 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 907 909 905 907 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
Genotype frequencies were compared between groups by chi-square (chi2) test on 2 x 2 or 3 x 2 contingency tables using Statistica software package (StatSoft Inc., Tulsa, OK) and p values less than 0.05 were considered significant. Additionally Bonferoni's correction for multiple testing was applied and a corrected p value (pc) is also presented. Odds ratios (OR) with 95% confidence intervals were calculated by the method of Woolf [17]. Linkage disequilibrium (LD) was analyzed using the pairwise LD measure D' and haplotype blocks were constructed from population genotype data with the use of Haploview software [18], using the default algorithm for generating haplotype blocks based on methods established by Gabriel et al. [19]. A D' value of 1 indicates complete LD between the two markers, D' value greater than 0.8 - strong LD, 0.2-0.8 - incomplete LD, whereas a D' less than 0.2 - negligible LD [20]. Power analysis was performed using the DSS software available online .
###end p 27
###begin title 28
Results
###end title 28
###begin title 29
Genotyping results, linkage disequilibrium analysis and construction of haplotypes
###end title 29
###begin p 30
###xml 15 20 15 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IKBL </italic>
###xml 24 31 24 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NFKBIA </italic>
###xml 113 114 113 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 53 61 <span type="species:ncbi:9606">patients</span>
Frequencies of IKBL and NFKBIA genotypes observed in patients with GD and in healthy subjects are shown in Table 2. All cases and controls in the studied cohorts were in Hardy-Weinberg equilibrium.
###end p 30
###begin p 31
###xml 16 21 16 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IKBL </italic>
###xml 25 32 25 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NFKBIA </italic>
###xml 45 53 <span type="species:ncbi:9606">patients</span>
Distribution of IKBL and NFKBIA genotypes in patients with Graves' disease (GD) and in healthy controls
###end p 31
###begin p 32
###xml 48 49 46 47 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 138 140 136 138 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs</italic>
###xml 173 175 171 173 <sub xmlns:xlink="http://www.w3.org/1999/xlink">c&gt;</sub>
* p value was calculated by a by chi-square (chi2) test using a 2 x 2 table to compare the frequency of genotypes possessing the A allele vs. TT homozygotes and corrected (pc>) for the number of tests performed.
###end p 32
###begin p 33
###xml 49 50 47 48 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 139 143 137 141 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs. </italic>
###xml 174 175 172 173 <sub xmlns:xlink="http://www.w3.org/1999/xlink">c</sub>
** p value was calculated by a by chi-square (chi2) test using a 2 x 2 table to compare the frequency of genotypes possessing the T allele vs. CC homozygotes and corrected (pc) for the number of tests performed.
###end p 33
###begin p 34
NS - non significant.
###end p 34
###begin p 35
###xml 36 41 36 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IKBL </italic>
###xml 87 91 87 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs. </italic>
###xml 111 113 111 113 <sub xmlns:xlink="http://www.w3.org/1999/xlink">c </sub>
###xml 225 227 225 227 <sub xmlns:xlink="http://www.w3.org/1999/xlink">c </sub>
###xml 358 362 358 362 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs. </italic>
###xml 381 383 381 383 <sub xmlns:xlink="http://www.w3.org/1999/xlink">c </sub>
###xml 600 604 600 604 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs. </italic>
###xml 622 624 622 624 <sub xmlns:xlink="http://www.w3.org/1999/xlink">c </sub>
###xml 792 796 792 796 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs. </italic>
###xml 815 817 815 817 <sub xmlns:xlink="http://www.w3.org/1999/xlink">c </sub>
###xml 898 903 898 903 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IKBL </italic>
###xml 342 350 <span type="species:ncbi:9606">patients</span>
###xml 776 784 <span type="species:ncbi:9606">patients</span>
The frequency of the allele -62A in IKBL was greater in GD compared to controls (39.0% vs. 30.4%, p = 0.0001, pc = 0.0018; OR = 1.46 [95% CI:1.20-1.77]). A significant association was also observed for genotypes (p = 0.001, pc = 0.018): genotypes possessing the A allele (AA homozygotes and AT heterozygotes) were found more frequently in GD patients (62.0% vs. 50.3%, p = 0.001, pc = 0.018) producing OR of 1.54 [95% CI:1.20-1.99] suggesting a dominant model of inheritance (statistical power - SP = 95.1%). For the intronic C/T substitution, an association of the T allele with GD was found (36.1% vs. 30.4%, p = 0.01, pc = 0.18; OR = 1.29 [95% CI:1.06-1.56]) and consistently, genotypes possessing this allele (TT homozygotes and CT heterozygotes) were more frequent in GD patients (61.3% vs. 51.0%, p = 0.001, pc = 0.018; OR = 1.52 [95% CI:1.18-1.98], SP = 88.9%). The T/C SNP in exon 4 of the IKBL was not associated with GD.
###end p 35
###begin p 36
###xml 24 29 24 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IKBL </italic>
###xml 137 142 137 142 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IKBL </italic>
###xml 224 226 224 226 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-4</sup>
###xml 234 235 234 235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 308 312 308 312 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs. </italic>
###xml 187 195 <span type="species:ncbi:9606">patients</span>
###xml 292 300 <span type="species:ncbi:9606">patients</span>
A strong LD between the IKBL promoter -62T/A and intron 1 C/T polymorphisms was observed (D' = 0.835). Subsequently, the distribution of IKBL haplotypes differed significantly between GD patients and healthy subjects (p < 10-4, Table 3), with an increased frequency of the AT haplotype in GD patients (34.6% vs. 24.6%, OR = 1.61 [95%CI: 1.21-2.14]).
###end p 36
###begin p 37
###xml 15 20 15 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IKBL </italic>
###xml 34 42 <span type="species:ncbi:9606">patients</span>
Frequencies of IKBL haplotypes in patients with Graves' disease (GD) and in healthy controls.
###end p 37
###begin p 38
###xml 220 225 220 225 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IKBL </italic>
###xml 307 309 307 309 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-4</sup>
###xml 270 278 <span type="species:ncbi:9606">patients</span>
Haploview software was used to construct haplotypes from population genotype data and to assess possible difference in their distribution between GD vs. healthy subjects (using a nonparametric test). The distribution of IKBL haplotypes differed significantly between GD patients and healthy subjects (p < 10-4).
###end p 38
###begin p 39
###xml 39 46 39 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NFKBIA </italic>
###xml 93 94 93 94 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
None of the three SNPs analyzed in the NFKBIA gene was found to be associated with GD (Table 2).
###end p 39
###begin title 40
Correlation with the clinical phenotype of GD
###end title 40
###begin p 41
###xml 16 21 16 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IKBL </italic>
###xml 25 32 25 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NFKBIA </italic>
###xml 74 82 <span type="species:ncbi:9606">patients</span>
Distribution of IKBL and NFKBIA genotypes was compared in subgroups of GD patients stratified by clinical parameters, including gender, age of GD onset, presence of clinically evident ophthalmopathy, family history of autoimmune thyroid diseases and smoking habits.
###end p 41
###begin p 42
###xml 53 60 53 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NFKBIA </italic>
###xml 237 238 237 238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 281 285 281 285 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs. </italic>
###xml 304 306 304 306 <sub xmlns:xlink="http://www.w3.org/1999/xlink">c </sub>
###xml 434 438 434 438 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs. </italic>
###xml 456 458 456 458 <sub xmlns:xlink="http://www.w3.org/1999/xlink">c </sub>
###xml 774 778 774 778 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs. </italic>
###xml 797 799 797 799 <sub xmlns:xlink="http://www.w3.org/1999/xlink">c </sub>
###xml 859 863 859 863 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs. </italic>
###xml 881 883 881 883 <sub xmlns:xlink="http://www.w3.org/1999/xlink">c </sub>
###xml 1048 1049 1048 1049 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T5">5</xref>
###xml 1072 1079 1072 1079 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NFKBIA </italic>
###xml 1321 1325 1319 1323 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs. </italic>
###xml 558 566 <span type="species:ncbi:9606">patients</span>
###xml 1284 1292 <span type="species:ncbi:9606">patients</span>
In case of two promoter polymorphisms studied in the NFKBIA gene an association with the development of clinically evident ophthalmopathy was detected, however, after Bonferroni adjustment, some results did not remain significant (Table 4). For the -297C/T SNP, the allele T (21.2%vs. 13.8%, p = 0.004; pc = 0.072; OR = 1.67 [95%CI: 1.18-2.38]), as well as genotypes inclusive this variant (TT homozygotes and CT heterozygotes; 37.1% vs. 26.3%, p = 0.01; pc = 0.18; OR = 1.65 [95%CI: 1.10-2.48], SP = 67.8%), were observed more frequently in the subgroup of patients with clinically evident ophthalmopathy. Similarly, for the -826C/T polymorphism, an association of the allele T (and genotypes possessing this allele) with the presence of ophthalmopathy was detected (23.2% vs. 15.2%, p = 0.002; pc = 0.036; OR = 1.68 [95%CI: 1.20-2.36] for alleles and 40.6% vs. 29.1%, p = 0.01; pc = 0.18; OR = 1.67 [95%CI: 1.12-2.48] for genotypes, SP = 71.1%). Since these two polymorphisms were in a strong LD, analysis of haplotypes was also performed (Table 5). The distribution of NFKBIA promoter haplotypes differed significantly between subgroups of GD subjects stratified by the presence of clinically evident ophthalmopathy (p = 0.003), with an increased frequency of the T*T haplotype in patients with NOSPECS >/= III (18.4% vs. 11.3%, OR = 1.73 [95%CI: 1.02-2.94]).
###end p 42
###begin p 43
###xml 16 21 16 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IKBL </italic>
###xml 25 32 25 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NFKBIA </italic>
###xml 58 66 <span type="species:ncbi:9606">patients</span>
Distribution of IKBL and NFKBIA genotypes in subgroups of patients with Graves' disease stratified by clinical activity of thyroid associated ophtalmopathy assessed according to the OSPECS classification.
###end p 43
###begin p 44
###xml 48 49 46 47 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 138 140 136 138 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs</italic>
###xml 173 174 171 172 <sub xmlns:xlink="http://www.w3.org/1999/xlink">c</sub>
* p value was calculated by a by chi-square (chi2) test using a 2 x 2 table to compare the frequency of genotypes possessing the T allele vs. CC homozygotes and corrected (pc) for the number of tests performed.
###end p 44
###begin p 45
###xml 14 22 <span type="species:ncbi:9606">patients</span>
N - number of patients available for analysis.
###end p 45
###begin p 46
NS - non significant.
###end p 46
###begin p 47
###xml 15 22 15 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NFKBIA </italic>
###xml 58 66 <span type="species:ncbi:9606">patients</span>
Frequencies of NFKBIA promoter haplotypes in subgroups of patients with Graves' disease stratified by clinical activity of thyroid associated ophtalmopathy assessed according to the NOSPECS classification.
###end p 47
###begin p 48
###xml 159 166 159 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NFKBIA </italic>
Haploview software was used to construct haplotypes from population genotype data and to assess possible difference in their distribution. The distribution of NFKBIA promoter haplotypes differed significantly between subgroups of GD subjects stratified by the presence of clinically evident ophthalmopathy (p = 0.003).
###end p 48
###begin p 49
###xml 42 47 42 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IKBL </italic>
###xml 51 58 51 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NFKBIA </italic>
No other associations between the studied IKBL and NFKBIA polymorphisms and the clinical phenotype of GD were observed (data not shown).
###end p 49
###begin title 50
Interaction studies with known susceptibility loci
###end title 50
###begin p 51
###xml 40 45 40 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IKBL </italic>
###xml 49 56 49 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NFKBIA </italic>
###xml 123 134 123 134 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA DRB1*03</italic>
###xml 136 142 136 142 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA4 </italic>
###xml 150 158 150 158 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTPN 22 </italic>
###xml 193 194 193 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S2">2</xref>
###xml 218 223 218 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IKBL </italic>
###xml 264 276 264 276 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA DRB1*03 </italic>
###xml 328 332 328 332 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs. </italic>
###xml 345 347 345 347 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-4</sup>
###xml 350 352 350 352 <sub xmlns:xlink="http://www.w3.org/1999/xlink">c </sub>
###xml 356 358 356 358 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-4</sup>
###xml 412 417 412 417 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IKBL </italic>
###xml 467 479 467 479 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA DRB1*03 </italic>
###xml 495 499 495 499 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs. </italic>
###xml 518 520 518 520 <sub xmlns:xlink="http://www.w3.org/1999/xlink">c </sub>
###xml 620 625 620 625 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IKBL </italic>
###xml 640 646 640 646 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA4 </italic>
###xml 675 679 675 679 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs. </italic>
###xml 697 699 697 699 <sub xmlns:xlink="http://www.w3.org/1999/xlink">c </sub>
###xml 83 91 <span type="species:ncbi:9606">patients</span>
###xml 659 667 <span type="species:ncbi:9606">patients</span>
Finally we analyzed the distribution of IKBL and NFKBIA alleles in subgroups of GD patients stratified by genetic markers: HLA DRB1*03, CTLA4 49G and PTPN 22 1858T alleles [see Additional file 2]. The frequency of the IKBL -62A allele was significantly greater in HLA DRB1*03 carriers compared to the rest of GD subjects (57.9% vs. 25.7%, p < 10-4, pc < 10-4, OR = 14.32 [95%CI: 7.02-29.22], SP = 100%). For the IKBL exon 4 T/C SNP, the T allele was more frequent in HLA DRB1*03 carriers (96.1% vs. 89.9%, p = 0.047, pc = 0.846; OR = 2.73 [95%CI: 0.98-7.60], SP = 52.2%). Moreover, we observed a higher frequency of the IKBL -62A allele in CTLA4 49G positive patients (65.4% vs. 53.7%, p = 0.02, pc = 0.36; OR = 1.62 [95%CI: 1.09-2.44], SP = 65.7%).
###end p 51
###begin title 52
Discussion
###end title 52
###begin p 53
###xml 95 100 91 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IKBL </italic>
###xml 124 131 116 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NFKBIA </italic>
The present study investigated a role of selected polymorphisms within genes encoding IkappaB: IKBL (encoding IkappaBL) and NFKBIA (encoding IkappaBalpha) in development of Grave's disease (GD) in the Polish population.
###end p 53
###begin p 54
###xml 146 151 146 151 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IKBL </italic>
###xml 182 187 182 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IKBL </italic>
###xml 338 345 338 345 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al. </italic>
###xml 346 348 346 348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 420 425 420 425 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IKBL </italic>
###xml 670 675 670 675 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IKBL </italic>
###xml 775 777 771 773 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 778 780 774 776 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 980 981 976 977 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 982 984 978 980 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 1120 1121 1116 1117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 1293 1298 1289 1294 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IKBL </italic>
###xml 1335 1337 1331 1333 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 1338 1340 1334 1336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 851 859 <span type="species:ncbi:9606">patients</span>
The first observation made in this study is a possible association of the two SNPs in the promoter (-62 T/A) and in the first intron (C/T) of the IKBL with susceptibility to GD. The IKBL gene is located on the telomeric end of the central MHC (major histocompatibility complex) on chromosome 6. Since it was initially described by Allock et al. [21], the -62 T/A SNP was found to disrupt an E-box binding element in the IKBL promoter - a sequence that can also be found in promoter and enhancer regions of the wide-variety of B and T cell lineage specific genes. Moreover, independent functional studies reported an association of the -62A allele with a decrease of the IKBL promoter activity that can result in disinhibition of the NF-kappaB mediated inflammatory response [22,23]. In our dataset we observed a higher frequency of the -62A allele in patients with GD compared to the healthy subjects. In Australians, this allele constituted a part of the diabetogenic haplotype [7,23]. On contrary, in the Japanese population an association between the -62T allele and development of rheumatoid arthritis was reported [6]. However, subsequent replication case-control and family-based studies failed to confirm this association in Caucasians, suggesting that genetic susceptibility linked to IKBL may vary in different ethnic groups [24,25].
###end p 54
###begin p 55
###xml 124 129 124 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IKBL </italic>
###xml 372 373 372 373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 557 559 557 559 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 937 942 937 942 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IKBL </italic>
###xml 957 968 957 968 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLADRB1*03 </italic>
###xml 1425 1427 1425 1427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 1640 1645 1640 1645 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IKBL </italic>
###xml 1654 1665 1654 1665 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLADRB1*03 </italic>
###xml 1742 1747 1742 1747 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IKBL </italic>
While possible consequences of the -62 T/A SNP are examined, the functional importance of the C/T substitution in the first IKBL intron remains unknown. In the present study we observed an association of the intron1 T allele with development of GD in Polish population. In the previous report the T allele was linked to the resistance to rheumatoid arthritis in Japanese [6] and to our knowledge, this SNP has not been studied in other autoimmune diseases. In general, intronic polymorphisms may act as markers linked to the functional, causative variants [26]. In the studied population we observed a strong linkage disequilibrium between the promoter -62 T/A and intron 1 C/T SNPs, and therefore we suppose that the observed association may be secondary to the linkage with the -62A allele. Moreover, a preliminary interaction analysis with the established GD susceptibility markers revealed a possible interaction between the studied IKBL variants and a HLADRB1*03 alleles - known as probably the most significant genetic predisposing factor to GD in Caucasians. However genes located within the MHC complex are in a strong linkage disequilibrium and certain alleles may occur in combination at a greater frequency than would be predicted by random association. This phenomenon hinders the distinction between genes primarily involved in conferring susceptibility to a disease and markers for the effect of a nearby gene [27]. Therefore, a further study involving HLA-DR genotyping of the Polish controls, as well as adequately powered replication studies in other Caucasian populations are required to determine the independent role of IKBL SNPs and HLADRB1*03 alleles in pathogenesis of Graves' disease. The possible interaction between IKBL SNPs and CTLA-4 49A/G polymorphism must be judged very cautiously (statistical power < 80% and pc > 0.05).
###end p 55
###begin p 56
###xml 51 57 47 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NFKBIA</italic>
###xml 279 280 275 276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 281 283 277 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 286 296 282 292 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In silico </italic>
###xml 395 402 387 394 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NFKBIA </italic>
###xml 512 513 504 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 514 516 506 508 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 975 977 967 969 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 1209 1211 1197 1199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 1274 1281 1262 1269 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NFKBIA </italic>
###xml 1518 1520 1498 1500 <sub xmlns:xlink="http://www.w3.org/1999/xlink">c </sub>
###xml 634 642 <span type="species:ncbi:9606">patients</span>
###xml 1055 1063 <span type="species:ncbi:9606">patients</span>
The second IkappaB gene analyzed in this study was NFKBIA. In previous reports two promoter polymorphisms within this gene (-826 C/T and -297 C/T substitutions) were associated with prevalence of rheumatoid arthritis and systemic lupus erythematosus in the Taiwanese population [9,10]. In silico analysis revealed that the -297 C/T SNP is situated close to the sites of NF-kappaB binding in the NFKBIA promoter. In turn, the -826 C/T substitution disrupts a putative binding site of transcription factor GATA-2 [9,10]. In our dataset, the comparison of genotype and allele frequencies of these SNPs revealed no differences between GD patients and healthy subjects. However, when correlated with phenotype, the -297T and -826T alleles (alone, as well as in a haplotype) were found to be associated with presence of clinically evident ophthalmophaty. Interestingly, these alleles have been previously associated with development of chronic inflammatory diseases in Caucasians [28]. It is reported that pharmacological inhibition of the NF-kappaB pathway in patients with active ophthalmophaty results in the suppression of inflammation and in the decreased glycosaminoglycans production by orbital fibroblasts [29]. Therefore it can be assumed that allelic differences in the NFKBIA promoter that affect IkappaBalpha expression may influence regulation of the inflammatory response in the orbit tissue. However the genotype-phenotype correlation should be treated as preliminary since the analysis was underpowered and pc > 0.05. Future replication studies are required to confirm our observation.
###end p 56
###begin title 57
Conclusion
###end title 57
###begin p 58
In conclusion, SNPs in genes encoding IkappaBL and IkappaBalpha may contribute to the development or clinical phenotype of GD. However, since it is not possible to conclude if these loci represent primary etiological variants, further replication and functional studies are required to evaluate a role of IkappaB polymorphisms in development of thyroid autoimmunity.
###end p 58
###begin title 59
Competing interests
###end title 59
###begin p 60
There is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.
###end p 60
###begin title 61
Authors' contributions
###end title 61
###begin p 62
AK carried out the molecular genetic studies, performed the statistical evaluation and drafted the manuscript, PM participated in acquisition of data, EBA and JN participated in design and coordination of the study, TB conceived of the study, participated in its design and coordination and revised the manuscript. All authors read and approved the manuscript.
###end p 62
###begin title 63
Supplementary Material
###end title 63
###begin title 64
Additional file 1
###end title 64
###begin p 65
###xml 79 84 79 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IKBL </italic>
###xml 88 95 88 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NFKBIA </italic>
###xml 0 100 0 100 <bold xmlns:xlink="http://www.w3.org/1999/xlink">PCR-RFLP conditions used for the analysis of the selected polymorphisms in the <italic>IKBL </italic>and <italic>NFKBIA </italic>genes</bold>
PCR-RFLP conditions used for the analysis of the selected polymorphisms in the IKBL and NFKBIA genes. The data provided describe experimental conditions used for the PCR-RFLP analysis.
###end p 65
###begin p 66
Click here for file
###end p 66
###begin title 67
Additional file 2
###end title 67
###begin p 68
###xml 16 21 16 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IKBL </italic>
###xml 0 96 0 96 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Distribution of <italic>IKBL </italic>genotypes in subgroups of patients with GD stratified by genetic parameters</bold>
###xml 159 164 159 164 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IKBL </italic>
###xml 264 275 264 275 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA DRB1*03</italic>
###xml 277 283 277 283 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA4 </italic>
###xml 291 299 291 299 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTPN 22 </italic>
###xml 47 55 <span type="species:ncbi:9606">patients</span>
###xml 203 211 <span type="species:ncbi:9606">patients</span>
Distribution of IKBL genotypes in subgroups of patients with GD stratified by genetic parameters. The data provided represents the statistical analysis of the IKBL genotypes distribution in subgroups of patients with GD stratified by genetic parameters including: HLA DRB1*03, CTLA4 49G and PTPN 22 1858T alleles.
###end p 68
###begin p 69
Click here for file
###end p 69
###begin title 70
Acknowledgements
###end title 70
###begin p 71
This work was supported by the Polish Ministry of Science and Higher Education Grant No. 2 PO5B 120 29.
###end p 71
###begin article-title 72
NF-kappa B as a therapeutic target in autoimmune disease
###end article-title 72
###begin article-title 73
NF-kappaB and the immune response
###end article-title 73
###begin article-title 74
Nuclear factor-kappaB: its role in health and disease
###end article-title 74
###begin article-title 75
Association of NFKB1 -94ins/del ATTG promoter polymorphism with susceptibility to and phenotype of Graves' disease
###end article-title 75
###begin article-title 76
Inhibitors in the NFkappaB cascade comprise prime candidate genes predisposing to multiple sclerosis, especially in selected combinations
###end article-title 76
###begin article-title 77
Identification of I kappa BL as the second major histocompatibility complex-linked susceptibility locus for rheumatoid arthritis
###end article-title 77
###begin article-title 78
Can MHC class II genes mediate resistance to type 1 diabetes?
###end article-title 78
###begin article-title 79
Inhibitors of kB-like gene polymorphisms in rheumatoid arthritis
###end article-title 79
###begin article-title 80
###xml 39 47 <span type="species:ncbi:9606">patients</span>
IkappaBalpha promoter polymorphisms in patients with rheumatoid arthritis
###end article-title 80
###begin article-title 81
###xml 42 50 <span type="species:ncbi:9606">patients</span>
I kappa B alpha promoter polymorphisms in patients with systemic lupus erythematosus
###end article-title 81
###begin article-title 82
###xml 39 47 <span type="species:ncbi:9606">patients</span>
IkappaBalpha promoter polymorphisms in patients with primary Sjogren's syndrome
###end article-title 82
###begin article-title 83
###xml 69 77 <span type="species:ncbi:9606">patients</span>
A polymorphism of the NFKBIA gene is associated with Crohn's disease patients lacking a predisposing allele of the CARD15 gene
###end article-title 83
###begin article-title 84
###xml 41 46 <span type="species:ncbi:9606">human</span>
Association of tumor necrosis factor and human leukocyte antigen DRB1 alleles with Graves' ophthalmopathy
###end article-title 84
###begin article-title 85
###xml 55 60 <span type="species:ncbi:9606">human</span>
A simple salting out procedure for extracting DNA from human nucleated cells
###end article-title 85
###begin article-title 86
Association of cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) gene polymorphism and non-genetic factors with Graves' ophthalmopathy in European and Japanese populations
###end article-title 86
###begin article-title 87
Lymphoid tyrosine phosphatase (PTPN22/LYP) variant and Graves' disease in a Polish population: association and gene dose-dependent correlation with age of onset
###end article-title 87
###begin article-title 88
On estimating the relation between blood group and disease
###end article-title 88
###begin article-title 89
Haploview: analysis and visualization of LD and haplotype maps
###end article-title 89
###begin article-title 90
###xml 41 46 <span type="species:ncbi:9606">human</span>
The structure of haplotype blocks in the human genome
###end article-title 90
###begin article-title 91
###xml 42 47 <span type="species:ncbi:9606">human</span>
Patterns of linkage disequilibrium in the human genome
###end article-title 91
###begin article-title 92
Haplotypic single nucleotide polymorphisms in the central MHC gene IKBL, a potential regulator of NF-kappaB function
###end article-title 92
###begin article-title 93
Functional SNPs in the lymphotoxin-alpha gene that are associated with susceptibility to myocardial infarction
###end article-title 93
###begin article-title 94
A promoter polymorphism in the central MHC gene, IKBL, influences the binding of transcription factors USF1 and E47 on disease-associated haplotypes
###end article-title 94
###begin article-title 95
Additional genetic susceptibility for rheumatoid arthritis telomeric of the DRB1 locus
###end article-title 95
###begin article-title 96
Lack of association between the I kappa BL promoter polymorphism and rheumatoid arthritis
###end article-title 96
###begin article-title 97
Association of the thyroid stimulating hormone receptor gene (TSHR) with Graves' disease
###end article-title 97
###begin article-title 98
Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants
###end article-title 98
###begin article-title 99
Inhibitor kappa B-alpha (IkappaB-alpha) promoter polymorphisms in UK and Dutch sarcoidosis
###end article-title 99
###begin article-title 100
###xml 83 88 <span type="species:ncbi:9606">human</span>
Leukoregulin upregulation of prostaglandin endoperoxide H synthase-2 expression in human orbital fibroblasts
###end article-title 100

